NPS Pharmaceuticals Given Average Rating of “Buy” by Brokerages (NASDAQ:NPSP)
Shares of NPS Pharmaceuticals (NASDAQ:NPSP) have received a consensus recommendation of “Buy” from the sixteen brokerages that are covering the stock, Analyst Ratings News reports. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $38.80.
A number of analysts have recently weighed in on NPSP shares. Analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $37.00 price target on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Tuesday, May 13th. They now have a $33.00 price target on the stock. Finally, analysts at Leerink Swann reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Friday, May 9th. They now have a $40.00 price target on the stock, down previously from $47.00.
NPS Pharmaceuticals (NASDAQ:NPSP) traded down 1.16% on Tuesday, hitting $34.96. The stock had a trading volume of 707,759 shares. NPS Pharmaceuticals has a one year low of $14.06 and a one year high of $39.68. The stock has a 50-day moving average of $27.95 and a 200-day moving average of $30.3. The company’s market cap is $3.717 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.02) by $0.04. The company had revenue of $44.04 million for the quarter, compared to the consensus estimate of $48.30 million. During the same quarter last year, the company posted ($0.09) earnings per share. NPS Pharmaceuticals’s revenue was up 73.2% compared to the same quarter last year. Analysts expect that NPS Pharmaceuticals will post $0.04 EPS for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.